Search Results - rakesh+singh

8 Results Sort By:
Small molecule for treatment of Acute Myelogenous Leukemia
­Background Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a fast-growing form of cancer of the blood and bone marrow. There are about 30,000 new cases of AML diagnosed per year in the USA, and the incidence is rising given the aging of the population. The current standard-of–care repertoire of therapies is often...
Published: 11/21/2022   |   Inventor(s): Rakesh Singh, Deepak Sahasrabudhe
Keywords(s):  
Category(s): Therapeutic
Septin inhibitors for treatment of cancer
Background Effective therapeutic options are limited for the treatment of liver, lung, renal, ovarian, endometrial and pancreatic cancer. Successive second- and third-line therapies do not add meaningful responses besides adding numerous life-debilitating toxicities. In order to improve the survival rate of patients diagnosed with these lethal malignancies,...
Published: 11/21/2022   |   Inventor(s): Richard Moore, Rakesh Singh, Kyu Kwang Kim, Rachael Turner
Keywords(s):  
Category(s): Therapeutic
Small molecule inhibitor of human epididymis protein 4 (HE4) for treating cancer
­Background Epithelial ovarian cancer (EOC), is the fifth leading cause of cancer deaths in women, and the deadliest of all gynecologic cancers. The response of current chemotherapies has plateaued, creating a severe unmet need for superior therapies. Human epididymis protein 4 (HE4) is inordinately overexpressed in over 70% of EOC patients, acts...
Published: 11/21/2022   |   Inventor(s): Richard Moore, Rakesh Singh, Kyu Kwang Kim
Keywords(s):  
Category(s): Therapeutic
Small molecule for the treatment of malignancies and immune disorders
­Background More than 23.5 million Americans (>7% of the population) are the existing or emerging consumers of drugs targeting autoimmune diseases alone not including immune-dependent malignancies, and the prevalence is rising. The global autoimmune disease therapeutics market size alone can exceed $125 billion by the year 2025. Similarly, immune...
Published: 12/12/2022   |   Inventor(s): Rakesh Singh, Richard Moore, Laura Calvi, Michael Becker
Keywords(s):  
Category(s): Therapeutic
URML-3881, a Novel MEK Inhibitor for the Treatment of Cancers
Provided herein, are compounds, compositions, and methods of treatment of cancers using an inhibitor of MAPK/ERK Kinase (MEK), in particular hydrazine derivatives.
Published: 11/21/2022   |   Inventor(s): Richard Moore, Rakesh Singh, Rachael Turner, Kyu Kwang Kim, Negar Khazan
Keywords(s):  
Category(s): Therapeutic
Therapy for Malignant Disease
Provided herein, inter alia, are methods and compositions directed to suppressing tumor cell growth in a subject as well as methods for sensitizing a proliferating cell for treatment with a cytotoxic agent via inhibiting expression of HE4 and one or more immune checkpoint inhibitors (ICIs). Also provided herein are methods for determining whether a...
Published: 11/21/2022   |   Inventor(s): Richard Moore, Rakesh Singh, Naohiro Yano
Keywords(s):  
Category(s): Therapeutic
Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7DHC) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human. In other aspects, the present invention provides a method...
Published: 11/21/2022   |   Inventor(s): Rakesh Singh, Richard Moore
Keywords(s):  
Category(s): Therapeutic
N-Amino Tetrahydrothiazine Derivatives, Methods of Manufacture and Use
This invention comprises the innovative synthesis of N-amino tetrahydrothiazine free bases and their salts. This invention further comprises the use of the derivatives and their therapeutic application as anticancer agents. Further this invention comprises their manufacture and use.
Published: 11/21/2022   |   Inventor(s): Rakesh Singh, Laurent Brard, Kyu Kwang Kim, Giselle Saulnier-Sholler
Keywords(s):  
Category(s): Therapeutic